Case report: Interstitial implantation radiotherapy combined with immunotherapy and GM-CSF in oligometastatic platinum-resistant ovarian cancer

被引：1
|
作者：
Qin, Yi [1 ]
Huang, Shangke [1 ]
Tang, Junli [1 ,2 ]
Fan, Yu [1 ]
Deng, Xiangyu [1 ]
Guan, Ping [1 ]
Zhang, Zhenhua [1 ]
Wen, Qinglian [3 ]
Li, Dan [1 ]
机构：
[1] Southwest Med Univ, Dept Oncol, Affiliated Hosp, Luzhou, Sichuan, Peoples R China
[2] First Peoples Hosp Suining, Dept Oncol, Suining, Sichuan, Peoples R China
[3] Sichuan Univ, West China Hosp, Canc Ctr, Dept Radiat Oncol, Chengdu, Sichuan, Peoples R China
来源：
FRONTIERS IN IMMUNOLOGY | 2024年 / 14卷
关键词：
platinum-resistant ovarian cancer; interstitial implantation radiotherapy; immunotherapy; GM-CSF; PRaG therapy; case report; RADIATION; COMBINATION; TUMORS; PEMBROLIZUMAB; CHEMOTHERAPY; INHIBITION; MECHANISMS; STRATEGIES; RESPONSES; THERAPY;
D O I：
10.3389/fimmu.2023.1329951
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
BackgroundTreatment for platinum-resistant ovarian cancer is challenging. Currently, platinum-resistant ovarian cancer is typically treated with non-platinum single-agent chemotherapy +/- bevacizumab, but the prognosis is often extremely poor. In the treatment of platinum-resistant ovarian cancer patients, reports of triple therapy with interstitial implantation radiotherapy combined with immunotherapy and granulocyte-macrophage colony-stimulating factor (GM-CSF) (PRaG for short) are relatively rare.Case descriptionHere, we report a patient with oligometastatic platinum-resistant ovarian cancer. The patient achieved partial response (PR) of the lesion and sustained benefit for more than six months after receiving interstitial implantation radiotherapy combined with immunotherapy along with GM-CSF.ConclusionThis triple therapy may provide additional options for these patients.
引用
收藏
页数：7
相关论文
共 50 条
  • [1] Immunotherapy for platinum-resistant ovarian cancer
    Bogani, Giorgio
    Lopez, Salvatore
    Mantiero, Mara
    Ducceschi, Monika
    Bosio, Sara
    Ruisi, Simona
    Sarpietro, Giuseppe
    Guerrisi, Rocco
    Brusadelli, Claudia
    Dell'Acqua, Andrea
    Di Donato, Violante
    Raspagliesi, Francesco
    GYNECOLOGIC ONCOLOGY, 2020, 158 (02) : 484 - 488
  • [2] Anlotinib combined with etoposide for platinum-resistant recurrent ovarian cancer A case report
    Sun, Li
    Yang, Meng
    Zhang, Xuan
    Li, Hua
    Wu, Lingying
    Zhang, Yuzi
    Cai, Shangli
    MEDICINE, 2020, 99 (20)
  • [3] A phase II trial of weekly nab-paclitaxel with GM-CSF as chemoimmunotherapy for platinum-resistant epithelial ovarian cancer.
    Swensen, R. E.
    Childs, J.
    Higgins, D.
    Gooley, T.
    Goff, B. A.
    Fintak, P. A.
    Buening, B.
    Disis, M. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] Unlocking the potential of immunotherapy in platinum-resistant ovarian cancer: rationale
    Kefas, Joanna
    Flynn, Michael
    CANCER DRUG RESISTANCE, 2024, 7
  • [5] Immunotherapy in the Treatment of Platinum-Resistant Ovarian Cancer: Current Perspectives
    Awada, Ahmad
    Ahmad, Sarfraz
    McKenzie, Nathalie D.
    Holloway, Robert W.
    ONCOTARGETS AND THERAPY, 2022, 15 : 853 - 866
  • [6] Final results of a phase II trial of weekly nab-paclitaxel with GM-CSF as chemoimmunotherapy for platinum-resistant epithelial ovarian cancer.
    Swensen, Ron E.
    Goff, Barbara Ann
    Childs, Jennifer
    Higgins, Doreen
    Gooley, Theodore
    Fintak, Patricia A.
    Buening, Barbara
    Disis, Mary L.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] Case Report and Review of Literature: Camrelizumab Combined with Fuzuloparib and Apatinib for Platinum-Resistant Recurrent Ovarian Cancer
    Wu, Yawen
    Zhang, Xiaoyan
    Li, Lian
    Yang, Wen
    Yan, Zhifeng
    Gu, Chenglei
    Zhang, Zhe
    Zhou, Jiahuan
    Liu, Lulu
    Ye, Mingxia
    Meng, Yuanguang
    ONCOTARGETS AND THERAPY, 2022, 15 : 973 - 979
  • [8] PD-1 inhibitor combined with radiotherapy and GM-CSF in MSS/pMMR metastatic colon cancer: a case report
    Yang, Jiabao
    Xing, Pengfei
    Kong, Yuehong
    Xu, Meiling
    Zhang, Liyuan
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [9] Complete response to Mirvetuximab Soravtansine in platinum-resistant recurrent ovarian cancer: a case report
    Wu, Yong
    Xia, Lingfang
    Song, Chunyan
    Chen, Xiaojun
    Wu, Xiaohua
    JOURNAL OF OVARIAN RESEARCH, 2025, 18 (01)
  • [10] Clinical observational study of conformal radiotherapy combined with topotecan chemotherapy in patients with platinum-resistant recurrent ovarian cancer
    Wei, P.
    Zhang, Z. H.
    Li, L.
    Du, X. L.
    Shan, C. P.
    Sheng, X. G.
    GENETICS AND MOLECULAR RESEARCH, 2015, 14 (02) : 3833 - 3842
12345